查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854505

mRNA療法市場依技術平台、治療應用及給藥方式分類－2025-2032年全球預測

mRNA Therapeutics Market by Technology Platform, Therapeutic Application, Delivery Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，mRNA 療法市場規模將達到 2,571.1 億美元，複合年成長率為 25.41%。

主要市場統計數據
基準年 2024 419.9億美元
預計年份：2025年 525.9億美元
預測年份：2032年 2571.1億美元
複合年成長率 (%) 25.41%

mRNA療法迎來了一個具有里程碑意義的時刻，科學突破、生產規模化需求和監管發展在此交匯融合，重塑了研發重點。

mRNA療法領域目前正處於科學檢驗、生產規模化和法律規範不斷演進的交匯點，這為研發人員、投資者和醫療監管機構創造了一個獨特的曲折點。核心平台技術的進步表明，遞送編碼的治療有效載荷可以引發持續且可控的生物反應，而製劑科學和低溫運輸物流的改進則降低了以往臨床應用的障礙。隨著計劃從概念驗證進入後期開發階段，相關人員臨著日益複雜的決策，涵蓋平台選擇、給藥途徑和特定治療的安全性評估等面向。

在此背景下，產業必須協調快速的技術進步與商業性執行的現實。投資重點正從純粹的研發活動轉向建構生產能力、品質保證和監管準備。同時，免疫學家、製劑科學家和製程工程師之間的跨領域合作對於加快研發進程和降低臨床風險至關重要。新監管指南的訂定和與支付方的討論進一步凸顯了整合策略的必要性。當前環境有利於那些能夠將技術差異化、可重複的臨床結果和永續供應鏈結合的企業。

平台成熟、製造現代化、監管協調和遞送途徑最佳化正在共同重塑 mRNA 療法的臨床和商業策略。

近期趨勢正在發生變革性變化，重新定義mRNA療法的研發、生產和遞送方式。平台演進是其中最重要的變化之一，脂質奈米顆粒化學和替代載體系統的最佳化顯著改善了生物分佈和耐受性。這項進步使得mRNA療法的應用範圍從疫苗擴展到慢性病和罕見疾病領域，從而拓展了治療前景。同時，生產技術的進步——例如連續生產、一次性系統和模組化設施設計——縮短了製程轉移前置作業時間，並提高了多產品生產工廠的靈活性。這些營運方面的改進降低了臨床批次規模化的門檻，並支持了更有效率的產品開發週期。

監管路徑也從臨時性的、針對特定適應症的指導方針，演變為更標準化的框架，以認可平台間的相似性。這些監管趨勢鼓勵申辦方設計利用平台資料包的研發項目，從而簡化後續的產品申報流程。肌肉注射、靜脈注射和皮下注射等給藥途徑正日益並行最佳化，以滿足不同的治療目標，這影響製劑、給藥策略和以患者為中心的考量。最後，商業模式也正在適應小型創新者與大型製造商之間合作日益普遍的現狀，使敏捷的科學能夠獲得所需的生產能力和市場推廣經驗，從而惠及更多患者。

美國2025年關稅政策的最新變化將如何影響mRNA療法研發的供應鏈架構、籌資策略和製造地選擇？

2025年美國關稅措施的累積影響將為mRNA治療供應鏈中的企業帶來一系列營運和策略的考量。關稅變化正在影響籌資策略，尤其是對脂質、核苷酸和特殊輔料等關鍵上游原料的採購，迫使企業團隊重新評估其供應商佈局和庫存緩衝。為此，許多公司正在實現供應商多元化，降低對單一國家的風險敞口，同時加快對貿易安排更為有利的國家和地區的替代供應商進行資格認證。這些措施正在重塑採購流程，並使供應商審核和品質監管變得更加複雜。

進口關稅的變化也影響物流和製造業的經濟效益，改變了關鍵零件和成品的到岸成本。這導致企業重新調整短期採購重點，轉而傾向於簽訂長期契約，並對供應受限的特種材料進行策略性儲備。企業也正在重新評估其生產佈局，考慮跨多個貿易區轉移或擴大產能所涉及的成本和監管週期。同時，製造商也在重新評估其合約策略，包括與合約開發和製造組織簽訂長期服務協議，以鎖定產能並減輕關稅制度變化帶來的營運波動。

最後，關稅環境凸顯了政策資訊在商業規劃中的重要性。研發團隊和企業領導者正與貿易和法律專家更緊密合作，模擬各種情境對成本結構和進度安排的影響。這種合作使企業能夠將關稅敏感性分析納入研發和供應連續性計劃，確保研發里程碑能夠應對外部貿易政策的變化。

策略性細分分析揭示了平台選擇、治療重點和給藥方式如何共同決定開發路徑和營運需求。

細分市場動態分析揭示了平台選擇、治療標靶和遞送方法如何相互作用，從而決定專案層面的策略和商業性管道。在考慮技術平台差異化時，脂質奈米顆粒已成為一種用途廣泛且應用廣泛的載體系統，支援全身和局部遞送。基於聚合物的平台因其可自訂的釋放動力學和模組化化學結構而備受關注，這些特性可以解決穩定性方面的限制。這些平台選擇使申辦方能夠根據其生物作用機制和生產能力來選擇合適的平台。

按治療用途進行細分可以進一步最佳化策略選擇。在心血管適應症方面，研發人員優先考慮給藥途徑和製劑穩定性，以最佳化組織標靶性和重複給藥的耐受性。在感染疾病，研發管道通常著重於免疫抗原性特徵和快速規模化生產，以應對疫情爆發。同時，罕見疾病通常需要量身定做的研發計劃，強調小規模生產、高效價製劑和以患者為中心的給藥方案。這些治療方法的差異也導致了不同的風險接受度、臨床試驗設計和商業化合作夥伴。

肌肉注射給藥支持分散給藥和廣泛的免疫宣傳活動，靜脈注射可實現複雜適應症的全身生物分佈，而皮下注射給藥則為慢性治療提供了更便捷的給藥方式。選擇合適的給藥途徑需要綜合考慮臨床目標、患者體驗和供應鏈實際情況。平台、應用和給藥方式之間的相互作用決定了計畫時間表、臨床終點的選擇以及確保計畫順利實施所需的生產能力。

全球各地區域政策、製造業生態系統和法規的差異，影響研發順序和供應鏈連續性策略。

區域動態在塑造mRNA療法的研發重點、監管環境和商業化策略方面發揮著至關重要的作用。在美洲，市場參與者必須適應一個以先進的臨床網路、活躍的風險投資和私募股權活動以及不斷完善指導方針以適應夥伴關係型應用為特徵的監管相關人員構成的生態系統。這些特點為加速後期臨床試驗、臨床檢驗和與支付方洽談的合作創造了沃土。該地區還擁有豐富的受託製造和開發服務生態系統，使申辦方能夠在無需資本密集型設施擴建的情況下擴大生產規模。

在歐洲、中東和非洲，不同司法管轄區的監管差異以及區域性衛生技術評估框架的存在，影響產品上市順序和證據產生的優先順序。在該地區營運的公司通常會透過集中提交監管文件（如適用）並根據各國報銷政策的細微差別調整策略，來規劃其臨床項目。此外，該地區也為與支持轉化和比較療效研究的學術中心和聯盟開展合作提供了機會。在亞太地區，市場動態呈現出多元化的特點，包括政府主導的強力的生產計劃、快速發展的臨床試驗能力以及對生物製造能力本土化的關注。這些市場的政策制定者越來越支持對生物技術和先進療法的投資，從而獎勵本地化生產和區域化供應鏈策略。

在所有地區，跨境合作仍然是推動複雜專案的關鍵槓桿。跨區域的監管互動、生產夥伴關係和臨床試驗中心網路對於縮短研發週期和確保供應連續性至關重要。因此，有效的區域策略應在檢驗全球平台的同時，針對每個區域制定量身定做的監管和商業性策略。

競爭格局表明，創新主導的合作、垂直製造整合和策略夥伴關係正在加速實驗室成果向臨床轉化。

mRNA療法領域的競爭格局反映了科學差異化、合作模式和垂直整合策略的融合。創新者優先考慮平台新穎性和臨床差異化，以確保有利的合作和許可協議；而現有生物製藥公司則通常透過收購或策略聯盟來快速獲取關鍵技術平台。合約研發受託製造公司則透過拓展製劑、無菌灌裝、低溫運輸物流等方面的能力來應對競爭，從而將自身定位為擴大臨床項目規模和支持商業化上市的重要合作夥伴。

各公司投資組合中呈現出幾種反覆出現的策略模式。首先，擁有強大平台智慧財產權和可靠臨床前證據的公司正利用選擇性合作關係來加速轉化活動，同時又不犧牲長期價值。其次，專注於慢性病應用的公司正在投資差異化的給藥方式和製劑，以實現重複給藥並提高患者依從性。第三，瞄準腫瘤和罕見疾病計畫的公司正在與專業臨床網路和病患權益組織建立更緊密的聯繫，以指導臨床試驗設計並加速病患招募。最後，專業製造公司和服務供應商正透過提供端到端的整合解決方案來提升自身競爭優勢，創造價值提案，從而減輕臨床試驗贊助者的協調負擔並縮短生產規模化週期。

為高階主管提供實際可行的高影響力建議，以加速研發進度、增強供應連續性，並使證據產生與支付方預期保持一致。

產業領導者可以採取一系列切實可行的措施來應對技術複雜性和商業性不確定性，同時加速專案成功。優先考慮與平台無關的開發管道，能夠幫助企業在分析、對比測試和監管溝通方面提升跨專案的效率。早期投資於製劑和給藥最佳化可以降低下游臨床風險，並提高患者接受度，尤其對於需要重複給藥的適應症。企業還應將供應連續性計畫納入開發時間表，在關鍵測試開始前充分驗證備用供應商和緊急生產安排，以減輕貿易和物流中斷對營運的影響。

從市場准入的角度來看，與契約製造和臨床網路建立策略夥伴關係，無需大量前期投資即可釋放產能並加快註冊流程。領導者還應建立監管情報機制，以追蹤不斷變化的指導意見，並針對不同適應症創建模組化、可重複使用的附加檔要素。商業團隊應儘早與支付者和衛生技術評估機構接洽，制定能夠展現超越傳統臨床終點價值的證據產生策略。最後，促進研發、生產、監管事務和商業規劃之間的跨職能管治，可以加快決策速度，確保科學進步轉化為可行的上市計劃和永續的產品生命週期。

採用嚴謹的多源研究途徑，結合專家訪談、監管審查、技術文獻綜述和情境分析，挖掘出可操作的行業考察。

本分析的研究結合了定性專家訪談、公開監管文件審查以及對近期科學文獻的跨領域綜合分析，從而全面展現了mRNA療法生態系統。研究人員與科學家、製程工程師、監管顧問、生產主管和商業策略師進行了專家對話，以了解營運情況並識別新興的最佳實踐。研究人員還查閱了監管材料和指導文件，以提供符合當前平台申報和生產可比性評估要求的見解。此外，研究人員還查閱了科學出版物和會議論文集，以了解載體化學、遞送管道和製劑穩定性數據的最新進展。

調查方法著重於三角驗證，檢驗定性輸入與同期政策變化和技術公告進行比對，以減少偏差並揭示穩健的趨勢。對代表性研發項目的案例分析提供了詳細資訊，闡明了平台選擇、給藥途徑和治療靶點如何帶來不同的風險和營運狀況。供應鏈情境規劃和關稅敏感性分析也被納入考量，以評估外部政策和物流因素如何影響專案的可行性。研究始終優先考慮與決策者相關的可操作性見解，重點關注對臨床設計、生產策略、監管互動和商業計劃的實際影響。

最後，我們整合了科學、營運和政策動態，這將決定哪些組織能夠將 mRNA 創新轉化為持續的臨床和商業性成功。

mRNA治療領域呈現出快速的技術進步、不斷變化的運作模式和持續演進的政策環境，這些因素共同帶來了巨大的機會和複雜的挑戰。載體技術的進步、生產製造的現代化以及遞送管道的最佳化，正在拓展mRNA治療的應用範圍；而監管和貿易的發展則要求更精細的風險管理和策略規劃。在這種環境下，能夠將卓越的科學研究實力與務實的供應鏈設計、穩健的監管策略以及早期與支付方的溝通相結合的機構，將更有機會取得成功。將敏捷的創新者與成熟的生產和商業化合作夥伴結合的協作模式，有望加速成果轉換並降低執行風險。

總之，推進這項工作需要採取平衡的方法，使平台和交付方式的選擇與臨床目標保持一致，預見供應和政策方面的阻力，並建立跨職能能力，將洞見轉化為可執行的專案。積極應對這些方面的機構將更有能力將科學前景轉化為持續的治療和商業性成果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 設計新型脂質奈米顆粒載體以增強組織特異性mRNA遞送
  • 整合自擴增mRNA平台可降低給藥頻率和成本。
  • 基於mRNA的癌症疫苗加速核准的監管途徑正在不斷發展。
  • 生技公司與學術界合作開發針對罕見疾病的個人化mRNA療法
  • 開發可提高體內穩定性和翻譯效率的DNA/mRNA雜合結構
  • 尋找新型佐劑以增強預防性mRNA免疫療法中的免疫反應
  • 擴大連續生產製程規模，實現經濟高效的大規模mRNA生產
  • 透過創新凍乾技術，推動低溫運輸物流發展，以促進mRNA疫苗的分發

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依技術平台分類的mRNA療法市場

  • 脂質奈米顆粒
  • 聚合物基
  • 病毒載體

第9章 mRNA療法市場：依治療應用分類

  • 心血管系統
  • 感染疾病
  • 腫瘤學
  • 罕見疾病

第10章 mRNA療法市場：依給藥方式分類

  • 肌肉內注射
  • 靜脈
  • 皮下

第11章 mRNA療法市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 mRNA療法市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國mRNA療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Moderna, Inc.
    • BioNTech SE
    • CureVac NV
    • Sanofi SA
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Arcturus Therapeutics Holdings, Inc.
    • Providence Therapeutics Holdings Inc.
    • Ethris GmbH
    • eTheRNA immunotherapies NV
Product Code: MRR-205091A88BBD

The mRNA Therapeutics Market is projected to grow by USD 257.11 billion at a CAGR of 25.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 41.99 billion
Estimated Year [2025] USD 52.59 billion
Forecast Year [2032] USD 257.11 billion
CAGR (%) 25.41%

A critical juncture in mRNA therapeutics where scientific breakthroughs, manufacturing scale demands, and regulatory developments converge to reshape development priorities

The field of mRNA therapeutics is now at the intersection of scientific validation, manufacturing scale-up, and evolving regulatory frameworks, creating a unique inflection point for developers, investors, and health authorities. Advances in core platform technologies have demonstrated that encoded delivery of therapeutic payloads can trigger durable and controllable biological responses, while parallel improvements in formulation science and cold-chain logistics have reduced historical barriers to clinical translation. As projects move from proof-of-concept to later-stage development, stakeholders face an increasingly complex set of decisions spanning platform selection, delivery routes, and therapy-specific safety profiles.

Against this backdrop, the industry must reconcile rapid technological progress with the practicalities of commercial execution. Investment priorities are shifting from purely discovery-focused activities to buildouts in manufacturing capacity, quality assurance, and regulatory readiness. Meanwhile, cross-disciplinary collaboration between immunologists, formulation scientists, and process engineers is becoming essential to accelerate timelines and mitigate clinical risk. The introduction of new regulatory guidances and payer discussions further underscores the need for integrated strategies that combine scientific rigor with pragmatic commercialization planning. Ultimately, the current environment rewards organizations that can translate technical differentiation into reproducible clinical outcomes and sustainable supply chains.

Platform maturation, manufacturing modernization, regulatory harmonization, and delivery route optimization are collectively remaking clinical and commercial strategies in mRNA therapeutics

Recent years have witnessed transformative shifts that are redefining how mRNA therapeutics are developed, manufactured, and delivered. Platform evolution is one of the most consequential shifts, as optimizations in lipid nanoparticle chemistry and alternative carrier systems have materially improved biodistribution and tolerability profiles. This progress has, in turn, enabled broader therapeutic ambitions beyond vaccine applications into chronic and rare disease indications. Simultaneously, advances in manufacturing technologies-continuous processing, single-use systems, and modular facility designs-have reduced lead times for process transfer and increased flexibility for multi-product plants. These operational improvements lower the threshold for scaling clinical batches and support more iterative product development cycles.

Regulatory pathways are also evolving from ad hoc, indication-specific guidance toward more standardized frameworks that recognize platform-based similarities. These regulatory trends are encouraging sponsors to design development programs that leverage platform data packages to streamline subsequent product filings. Another major shift is the growing emphasis on delivery modality; intramuscular, intravenous, and subcutaneous routes are now being optimized in parallel for distinct therapeutic goals, which has implications for formulation, dosing strategies, and patient-centric considerations. Finally, commercial models are adapting to a landscape where partnerships between small innovators and large-scale manufacturers are increasingly commonplace, enabling nimble science to access the production capacity and market access expertise necessary for broader patient reach.

How recent United States tariff shifts in 2025 are reshaping supply chain architecture, procurement strategies, and manufacturing footprint decisions across mRNA therapeutic development

The cumulative impact of the United States tariff policy developments in 2025 introduces a series of operational and strategic considerations for organizations involved in the mRNA therapeutics supply chain. Tariff changes have influenced sourcing strategies for key upstream inputs, particularly lipids, nucleotides, and specialized excipients, causing teams to re-evaluate supplier footprints and inventory buffers. In response, many organizations have initiated supplier diversification efforts to reduce single-country exposure, while others have accelerated qualification of alternative vendors in jurisdictions with more favorable trade arrangements. These efforts are reshaping procurement timelines and adding complexity to supplier audits and quality oversight.

Logistics and manufacturing economics have also been affected, as changes in import duties alter landed costs for critical components and finished goods. The result is a recalibration of near-term procurement priorities, with increased emphasis on long-lead contracts and strategic stockpiling for materials that are both specialized and supply-constrained. Companies are also reassessing their manufacturing footprints, weighing the costs and regulatory time associated with relocating or expanding production capacity in multiple trade zones. In parallel, manufacturers are rethinking contracting strategies, including longer-term service agreements with contract development and manufacturing organizations to lock in capacity and mitigate the operational variability introduced by shifting tariff regimes.

Finally, the tariff environment has underscored the importance of policy intelligence as part of commercial planning. Development teams and business leaders are collaborating more closely with trade and legal experts to model scenario impacts on cost structures and timelines. This alignment is prompting organizations to incorporate tariff sensitivity analyses into their go-to-market and supply continuity plans, ensuring that development milestones remain resilient to external trade policy changes.

Strategic segmentation analysis revealing how platform choices, therapeutic target priorities, and delivery modalities jointly determine development paths and operational needs

Insight into segmentation dynamics reveals how platform choices, therapeutic targets, and delivery methods interact to define program-level strategies and commercial pathways. When considering technology platform differentiation, lipid nanoparticles have emerged as a versatile and widely adopted carrier system that supports systemic and local delivery ambitions; polymer-based platforms are attracting interest for tailored release kinetics and modular chemistry that can address stability constraints; viral vectors continue to be explored for applications where high transduction efficiency is essential, particularly when long-term expression or cell-specific targeting is required. Together, these platform options compel sponsors to align platform selection with the biological mechanism of action and manufacturing capabilities.

Therapeutic application segmentation further refines strategic choices. For cardiovascular indications, developers prioritize delivery routes and formulation stability that optimize tissue targeting and repeat dosing tolerability. In infectious diseases, development pathways often emphasize immunogenicity profiles and rapid scalability to address outbreak scenarios. Oncology programs center on tumor targeting, dosing intensity, and combination strategies with existing modalities, while rare diseases frequently demand bespoke development plans that emphasize small-batch manufacturing, high-potency formulation, and patient-centered administration modalities. These therapeutic distinctions drive different risk tolerances, clinical trial designs, and commercialization partners.

Delivery method segmentation is equally consequential, as intramuscular administration supports decentralized delivery and broad immunization campaigns, intravenous approaches enable systemic biodistribution for complex indications, and subcutaneous routes offer patient-friendly dosing possibilities for chronic therapies. Selecting the appropriate delivery modality requires integrating clinical goals, patient experience considerations, and supply-chain realities, since each route carries distinct formulation and stability requirements. The interplay among platform, application, and delivery modality shapes program timelines, clinical endpoint selection, and the types of manufacturing competencies required to execute reliably.

Regional policy, manufacturing ecosystems, and regulatory variability across global territories that shape development sequencing and supply continuity strategies

Regional dynamics play a decisive role in shaping R&D priorities, regulatory pathways, and commercialization strategies across the mRNA therapeutics landscape. In the Americas, market actors must navigate an ecosystem characterized by advanced clinical networks, strong venture and private-equity activity, and regulatory agencies that are refining guidance to accommodate platform-based submissions. These features create fertile ground for late-stage trials and partnerships that can accelerate clinical validation and payer discussions. The region also features a dense contract manufacturing and development services ecosystem, offering sponsors multiple pathways to scale production without immediate capital-intensive facility expansion.

In Europe, Middle East & Africa, regulatory heterogeneity across jurisdictions and the presence of regional health technology assessment frameworks influence go-to-market sequencing and evidence generation priorities. Companies operating in this region often map clinical programs to achieve both centralized regulatory filings where appropriate and tailored national strategies to address reimbursement nuances. Additionally, the region presents collaboration opportunities with academic centers and consortiums that can support translational research and comparative effectiveness studies. In Asia-Pacific, diverse market dynamics include strong government-led manufacturing initiatives, rapidly scaling clinical trial capacity, and interest in domesticizing biomanufacturing capabilities. Policymakers across these markets are increasingly supportive of biotech and advanced therapy investments, creating incentives for local production and regionally focused supply chain strategies.

Across all regions, cross-border collaboration remains a key enabler for advancing complex programs. Regulatory dialogue, manufacturing partnerships, and clinical site networks that span multiple geographies are instrumental for accelerating development timelines and ensuring supply continuity. Effective regional strategies therefore balance global platform validation with locally tailored regulatory and commercial approaches.

Competitive patterns showing innovation-led alliances, vertical integration in manufacturing, and strategic partnerships that accelerate translation from lab to clinic

Competitive behavior in the mRNA therapeutics space reflects a mix of scientific differentiation, partnership models, and vertical integration strategies. Innovators prioritize platform novelty and clinical differentiation to secure advantageous partnering or licensing agreements, while established biopharma players typically pursue acquisition or strategic collaboration to gain rapid access to leading technology platforms. Contract development and manufacturing organizations are responding by expanding capabilities across formulation, aseptic fill-finish, and cold-chain logistics, positioning themselves as essential partners for scaling clinical programs and supporting commercial launches.

Across corporate portfolios, several recurring strategic patterns emerge. First, companies with strong platform IP and robust preclinical evidence are leveraging selective alliances to accelerate translational activities without relinquishing long-term value. Second, organizations focused on chronic disease applications are investing in delivery and formulation differentiation to enable repeated dosing and improve patient adherence. Third, firms targeting oncology and rare disease programs are building close relationships with specialized clinical networks and patient advocacy groups to inform trial design and accelerate enrollment. Finally, manufacturing-focused firms and service providers are carving out competitive moats by offering integrated end-to-end solutions, creating value propositions that reduce the coordination burden for sponsors and compressed timelines for production scale-up.

Practical, high-impact recommendations for executives to accelerate development timelines, strengthen supply continuity, and align evidence generation with payer expectations

Industry leaders can adopt a set of actionable practices to navigate technological complexity and commercial uncertainty while accelerating program success. Prioritizing platform-agnostic development pathways allows organizations to capture cross-program efficiencies in analytics, comparability studies, and regulatory engagements. Investing early in formulation and delivery optimization reduces downstream clinical risk and improves patient acceptability, particularly for indications that require repeat dosing. Companies should also embed supply continuity planning into their development timelines, validating secondary suppliers and contingency manufacturing arrangements well before pivotal studies begin, which mitigates the operational impact of trade or logistics disruptions.

From a go-to-market perspective, establishing strategic partnerships with contract manufacturers and clinical networks can unlock capacity and expedite enrollment without large upfront capital commitments. Leaders should also institutionalize regulatory intelligence functions to track evolving guidances and create modular dossier elements that can be repurposed across indications. Commercial teams must engage with payers and health technology assessors early to shape evidence generation strategies that demonstrate value beyond traditional clinical endpoints. Finally, cultivating cross-functional governance that aligns R&D, manufacturing, regulatory affairs, and commercial planning will accelerate decision-making and ensure that scientific advances translate into executable launch plans and sustainable product lifecycles.

A rigorous, multi-source research approach combining expert interviews, regulatory review, technical literature synthesis, and scenario analysis to surface actionable industry insights

The research underpinning this analysis combined qualitative expert interviews, public regulatory documentation reviews, and cross-disciplinary synthesis of recent scientific literature to ensure a comprehensive view of the mRNA therapeutics ecosystem. Expert conversations were conducted with scientists, process engineers, regulatory advisors, manufacturing executives, and commercial strategists to capture operational realities and identify emergent best practices. Regulatory source materials and guidance documents were examined to align insights with current expectations for platform-based submissions and manufacturing comparability assessments. Scientific publications and conference proceedings were reviewed to capture the latest advances in carrier chemistry, delivery routes, and formulation stability data.

The methodology emphasized triangulation: qualitative inputs were cross-validated against contemporaneous policy shifts and technical publications to reduce bias and surface robust trends. Case-level analyses of representative development programs provided granularity on how platform choice, delivery route, and therapeutic target drive different risk and operational profiles. Supply chain scenario planning and tariff sensitivity reviews were integrated to assess how external policy and logistics factors influence program viability. Throughout, the approach prioritized actionable insights relevant to decision-makers, focusing on practical implications for clinical design, manufacturing strategy, regulatory interactions, and commercial planning.

Final synthesis of scientific, operational, and policy dynamics that determine which organizations will convert mRNA innovation into durable clinical and commercial success

The mRNA therapeutics landscape is characterized by rapid technical progress, shifting operational paradigms, and evolving policy environments that together present both significant opportunities and complex challenges. Progress in carrier technologies, manufacturing modernization, and delivery route optimization has expanded the range of feasible therapeutic applications, while regulatory and trade developments require more sophisticated risk management and strategic planning. Success in this environment will favor organizations that integrate scientific excellence with pragmatic supply chain design, robust regulatory strategies, and early payer engagement. Collaborative approaches that pair nimble innovators with established manufacturing or commercialization partners are likely to accelerate translation and reduce executional risk.

In conclusion, the path forward requires a balanced approach that aligns platform and delivery selection with clinical objectives, anticipates supply and policy headwinds, and builds cross-functional capabilities to translate insights into deliverable programs. Organizations that proactively address these dimensions will be better positioned to convert scientific promise into durable therapeutic and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Engineering novel lipid nanoparticle vectors to enhance tissue-specific mRNA delivery
  • 5.2. Integration of self-amplifying mRNA platforms to lower dosing frequency and costs
  • 5.3. Regulatory pathways evolving for accelerated approval of mRNA-based cancer vaccines
  • 5.4. Collaborations between biotech firms and academia to develop personalized mRNA therapeutics for rare diseases
  • 5.5. Development of hybrid DNA/mRNA constructs to improve stability and translation efficiency in vivo
  • 5.6. Exploration of novel adjuvants to potentiate immune response in prophylactic mRNA immunotherapies
  • 5.7. Scale-up of continuous manufacturing processes for cost-effective large-scale mRNA production
  • 5.8. Addressing cold chain logistics by innovating lyophilization techniques for mRNA vaccine distribution

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Therapeutics Market, by Technology Platform

  • 8.1. Lipid Nanoparticles
  • 8.2. Polymer Based
  • 8.3. Viral Vectors

9. mRNA Therapeutics Market, by Therapeutic Application

  • 9.1. Cardiovascular
  • 9.2. Infectious Diseases
  • 9.3. Oncology
  • 9.4. Rare Diseases

10. mRNA Therapeutics Market, by Delivery Method

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. mRNA Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. mRNA Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. mRNA Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Moderna, Inc.
    • 14.3.2. BioNTech SE
    • 14.3.3. CureVac N.V.
    • 14.3.4. Sanofi S.A.
    • 14.3.5. Pfizer Inc.
    • 14.3.6. GlaxoSmithKline plc
    • 14.3.7. Arcturus Therapeutics Holdings, Inc.
    • 14.3.8. Providence Therapeutics Holdings Inc.
    • 14.3.9. Ethris GmbH
    • 14.3.10. eTheRNA immunotherapies NV

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 79. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 116. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 121. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 124. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 125. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 128. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 142. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 143. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 146. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 147. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 150. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 151. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 154. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 163. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 166. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 167. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 170. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 171. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 174. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 175. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 178. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 179. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 182. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 183. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 186. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 195. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 197. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 201. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 203. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 207. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 209. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 219. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 221. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 225. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 226. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 227. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 231. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 232. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 233. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 236. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 237. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 239. ITALY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. ITALY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 243. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 245. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 249. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 250. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 251. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 254. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 255. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 256. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 257. INDIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. INDIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. INDIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 260. INDIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 261. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 262. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 263. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 266. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 267. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 272. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 274. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 275. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 278. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 279. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 280. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024